Impaired inhibition of P2Y12 by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 465-472

  El Ghannudi, S ^a   Ohlmann, P ^a   Jesel, L ^a   Radulescu, B ^a   El Adraa, E ^a   Crimizade, U ^a   Wiesel, M L ^a   Gachet, C ^a   Morel, O ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Acute coronary syndrome; Platelet; Resistance; Stent thrombosis; Thienopyridines

Indexed keywords

CLOPIDOGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; DRUG DERIVATIVE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG RESPONSE; FLOW CYTOMETRY; FOLLOW UP; HEART DEATH; HUMAN; LOW PLATELET RESPONSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY INDEX; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; BLOOD; BLOOD CLOTTING PARAMETERS; CHI SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FRANCE; HEART DISEASE; HEART INFARCTION; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; FRANCE; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960728693     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.039     Document Type: Article

References (27)

1. Moreno P.R., Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004, 44:2293-2300.
2. Muller K., Aichele S., Herkommer M., et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010, 213:256-262.
3. Morel O., Kessler L., Ohlmann P., Bareiss P. Diabetes and the platelet: toward new paradigm in diabetic atherothrombosis. Atherosclerosis 2010, 212:367-376.
4. Angiolillo D.J. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009, 32:531-540.
5. Angiolillo D.J., Bernardo E., Sabate M., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007, 50:1541-1547.
6. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92.
7. El Ghannudi S., Ohlmann P., Meyer N., et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC Cardiovasc Intervent 2010, 3:648-656.
8. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007, 50:501-508.
9. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 17:2126-2130.
10. Angiolillo D.J., Bernardo E., Ramirez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006, 48:298-304.
11. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
12. Geisler T., Anders N., Paterok M., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007, 30:372-374.
13. Mangiacapra F., Patti G., Peace A., et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010, 106:619-623.
14. Gachet C., Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl 2008, 10(Suppl. A):A28-A34.
15. Ang L., Palakodeti V., Khalid A., et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008, 52:1052-1059.
16. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004, 24:1980-1987.
17. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
18. Morel O., El Ghannudi S., Jesel L., et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011, 57:399-408.
19. Angiolillo D.J. Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2007, 14:124-131.
20. Ferreira I.A., Mocking A.I., Feijge M.A., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006, 26:417-422.
21. Erlinge D., Varenhorst C., Braun O.O., et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008, 52:1968-1977.
22. Trenk D., Hochholzer W., Fromm M.F., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51:1925-1934.
23. Bouman H.J., Schomig E., van Werkum J.W., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2010, 17:110-116.
24. Flekac M., Skrha J., Zidkova K., Lacinova Z., Hilgertova J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008, 57:717-726.
25. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933.
26. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
27. James S., Angiolillo D.J., Cornel J.H., et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010, 31:3006-3016.